BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 36359564)

  • 1. Early Prediction and Monitoring of Treatment Response in Gastrointestinal Stromal Tumors by Means of Imaging: A Systematic Review.
    Weeda YA; Kalisvaart GM; van Velden FHP; Gelderblom H; van der Molen AJ; Bovee JVMG; van der Hage JA; Grootjans W; de Geus-Oei LF
    Diagnostics (Basel); 2022 Nov; 12(11):. PubMed ID: 36359564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of F-18 FDG PET/CT for predicting malignant potential of gastrointestinal stromal tumors: A systematic review and meta-analysis.
    Kim SJ; Lee SW
    J Gastroenterol Hepatol; 2018 Mar; 33(3):576-582. PubMed ID: 28994187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
    Gayed I; Vu T; Iyer R; Johnson M; Macapinlac H; Swanston N; Podoloff D
    J Nucl Med; 2004 Jan; 45(1):17-21. PubMed ID: 14734662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual-Energy CT Vital Iodine Tumor Burden for Response Assessment in Patients With Metastatic GIST Undergoing TKI Therapy: Comparison With Standard CT and FDG PET/CT Criteria.
    Meyer M; Hohenberger P; Overhoff D; Bartsch A; Henzler T; Haubenreisser H; Ronald J; Schmidt B; Flohr T; Sedlmair M; Ota H; Messiou C; Schoenberg SO; Riedel RF; Nelson RC; Marin D
    AJR Am J Roentgenol; 2022 Apr; 218(4):659-669. PubMed ID: 34668385
    [No Abstract]   [Full Text] [Related]  

  • 6. Long-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumor: A multicenter, 2-stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07).
    Montemurro M; Cioffi A; Dômont J; Rutkowski P; Roth AD; von Moos R; Inauen R; Toulmonde M; Burkhard RO; Knuesli C; Bauer S; Cassier P; Schwarb H; Le Cesne A; Koeberle D; Bärtschi D; Dietrich D; Biaggi C; Prior J; Leyvraz S
    Cancer; 2018 Apr; 124(7):1449-1454. PubMed ID: 29315500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of FDG-PET/CT for evaluating early response to induction chemotherapy in head and neck squamous cell carcinoma: A systematic review.
    Dos Anjos RF; Dos Anjos DA; Vieira DL; Leite AF; Figueiredo PTS; de Melo NS
    Medicine (Baltimore); 2016 Aug; 95(32):e4450. PubMed ID: 27512861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging therapy response of gastrointestinal stromal tumors (GIST) with FDG PET, CT and MRI: a systematic review.
    Dimitrakopoulou-Strauss A; Ronellenfitsch U; Cheng C; Pan L; Sachpekidis C; Hohenberger P; Henzler T
    Clin Transl Imaging; 2017; 5(3):183-197. PubMed ID: 29104864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multimodal functional imaging for early response assessment in patients with gastrointestinal stromal tumor treated with tyrosine kinase inhibitors.
    Revheim ME; Hole KH; Mo T; Bruland ØS; Reitan E; Julsrud L; Seierstad T
    Acta Radiol; 2022 Aug; 63(8):995-1004. PubMed ID: 34171968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic review and modelling of the cost-effectiveness of cardiac magnetic resonance imaging compared with current existing testing pathways in ischaemic cardiomyopathy.
    Campbell F; Thokala P; Uttley LC; Sutton A; Sutton AJ; Al-Mohammad A; Thomas SM
    Health Technol Assess; 2014 Sep; 18(59):1-120. PubMed ID: 25265259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can 3'-deoxy-3'-(18)F-fluorothymidine or 2'-deoxy-2'-(18)F-fluoro-d-glucose PET/CT better assess response after 3-weeks treatment by epidermal growth factor receptor kinase inhibitor, in non-small lung cancer patients? Preliminary results.
    Bhoil A; Singh B; Singh N; Kashyap R; Watts A; Sarika S; Mittal BR
    Hell J Nucl Med; 2014; 17(2):90-6. PubMed ID: 24997081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The value of (18) F-fluorodeoxyglucose positron emission tomography for prediction of treatment response in gastrointestinal stromal tumors: a systematic review and meta-analysis.
    Hassanzadeh-Rad A; Yousefifard M; Katal S; Asady H; Fard-Esfahani A; Moghadas Jafari A; Hosseini M
    J Gastroenterol Hepatol; 2016 May; 31(5):929-35. PubMed ID: 26642423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. F-18 FDG PET, CT, and MRI for detecting the malignant potential in patients with gastrointestinal stromal tumors: A protocol for a network meta-analysis of diagnostic test accuracy.
    Wei K; Pan B; Yang H; Lu C; Ge L; Cao N
    Medicine (Baltimore); 2018 Apr; 97(16):e0389. PubMed ID: 29668594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastrointestinal stromal tumours: correlation of F-FDG gamma camera-based coincidence positron emission tomography with CT for the assessment of treatment response--an AGITG study.
    Goldstein D; Tan BS; Rossleigh M; Haindl W; Walker B; Dixon J
    Oncology; 2005; 69(4):326-32. PubMed ID: 16293972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic Performance of ¹⁸F-FDG PET and PET/CT for the Detection of Recurrent Esophageal Cancer After Treatment with Curative Intent: A Systematic Review and Meta-Analysis.
    Goense L; van Rossum PS; Reitsma JB; Lam MG; Meijer GJ; van Vulpen M; Ruurda JP; van Hillegersberg R
    J Nucl Med; 2015 Jul; 56(7):995-1002. PubMed ID: 25952733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings.
    Choi H; Charnsangavej C; de Castro Faria S; Tamm EP; Benjamin RS; Johnson MM; Macapinlac HA; Podoloff DA
    AJR Am J Roentgenol; 2004 Dec; 183(6):1619-28. PubMed ID: 15547201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging and clinicopathologic features of esophageal gastrointestinal stromal tumors.
    Winant AJ; Gollub MJ; Shia J; Antonescu C; Bains MS; Levine MS
    AJR Am J Roentgenol; 2014 Aug; 203(2):306-14. PubMed ID: 25055264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Additional Value of [
    Yokoyama K; Tsuchiya J; Nakamoto Y; Tateishi U
    Diagnostics (Basel); 2021 Mar; 11(3):. PubMed ID: 33800310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring therapy with MEK inhibitor U0126 in a novel Wilms tumor model in Wt1 knockout Igf2 transgenic mice using 18F-FDG PET with dual-contrast enhanced CT and MRI: early metabolic response without inhibition of tumor growth.
    Flores LG; Yeh HH; Soghomonyan S; Young D; Bankson J; Hu Q; Alauddin M; Huff V; Gelovani JG
    Mol Imaging Biol; 2013 Apr; 15(2):175-85. PubMed ID: 22875335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diffusion-weighted magnetic resonance imaging in metastatic gastrointestinal stromal tumor (GIST): a pilot study on the assessment of treatment response in comparison with 18F-FDG PET/CT.
    Schmidt S; Dunet V; Koehli M; Montemurro M; Meuli R; Prior JO
    Acta Radiol; 2013 Oct; 54(8):837-42. PubMed ID: 23761549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.